Empagliflozin in adults hospitalised with COVID-19: a (null) hypothesis for RECOVERY
- PMID: 37865100
- DOI: 10.1016/S2213-8587(23)00263-2
Empagliflozin in adults hospitalised with COVID-19: a (null) hypothesis for RECOVERY
Conflict of interest statement
MG reports grants, consulting, or speaking honoraria from Eli Lilly, and consulting for Bayer. GP reports consulting, advisory board, or speaking honoraria from Eli Lilly, consulting or participation on advisory boards for Bayer, and consulting for Novo Nordisk.
Comment on
-
Empagliflozin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.Lancet Diabetes Endocrinol. 2023 Dec;11(12):905-914. doi: 10.1016/S2213-8587(23)00253-X. Epub 2023 Oct 18. Lancet Diabetes Endocrinol. 2023. PMID: 37865101 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical